Article Text

Download PDFPDF
EP360 Single-agent amrubicin therapy for recurrent small cell neuroendocrine cervical carcinoma
  1. S Minobe
  1. Gynecol, Hokkaidou Cancer Center, Sapporo, Japan


Introduction/Background Small cell neuroendocrine cervical cancer (SCNCC) is a highly aggressive tumor, and there is currently no standard treatment for recurrent SCNCC.

Methodology We treated three patients with recurrent SCNCC who had received prior etoposide/cisplatin chemotherapy with single-agent amrubicin (35 mg/m2, days 1–3).

Results Partial response was achieved in one patient who had no signs of disease progression 14 months after commencing amrubicin. This patient received a total of 10 cycles of amrubicin every 3 weeks, with acceptable adverse effects. Amrubicin treatment was unsuccessful and was discontinued in the other two patients; one received a total of five cycles of amrubicin with acceptable adverse effect, but amrubicin was discontinued because of disease progression, and the other discontinued amrubicin after only two cycles because of grade 4 neutropenia/thrombocytopenia.

Conclusion This report introduces the possibility that patient with recurrent SCNCC may benefit from the administration of low-dose AMR (35 mg/m2).

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.